The prognostic landscape of genes and infiltrating immune cells across human cancers

Nature Medicine

Volumn 21, Issue 8, 2015, Pages 938-945

  Gentles, Andrew J ^a   Newman, Aaron M ^b   Liu, Chih Long ^b   Bratman, Scott V ^a,b,d,e   Feng, Weiguo ^a,b   Kim, Dongkyoon ^b   Nair, Viswam S ^b   Xu, Yue ^a   Khuong, Amanda ^a   Hoang, Chuong D ^a,d,e   Diehn, Maximilian ^a,b,c   West, Robert B ^b   Plevritis, Sylvia K ^a   Alizadeh, Ash A ^a,b,c  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD161 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER SURVIVAL; CELL INFILTRATION; COLON CANCER; EWING SARCOMA; GENE EXPRESSION; GENETIC ASSOCIATION; GERM CELL TUMOR; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOCOMPETENT CELL; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; LUNG CANCER; MELANOMA; MESOTHELIOMA; META ANALYSIS; MULTIPLE MYELOMA; NEOPLASM; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PLASMA CELL; PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; STOMACH CANCER; TUMOR ASSOCIATED LEUKOCYTE; GENETICS; IMMUNOLOGY; MORTALITY; NEUTROPHIL CHEMOTAXIS; PHYSIOLOGY; PROGNOSIS;

HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; NEUTROPHIL INFILTRATION; PLASMA CELLS; PROGNOSIS;

EID: 84938984463     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3909     Document Type: Article

References (80)

1. Coussens, L.M. & Werb, Z. Inflammation and cancer. Nature 420, 860-867 (2002).
2. Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203-213 (2003).
3. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454 (2012).
4. Fan, J.B., Chee, M. & Gunderson, K. Highly parallel genomic assays. Nat. Rev. Genet. 7, 632-644 (2006).
5. Koscielny, S. Why most gene expression signatures of tumors have not been useful in the clinic. Sci. Transl. Med. 2, ps2 (2010).
6. Dupuy, A. & Simon, R.M. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl. Cancer Inst. 99, 147-157 (2007).
7. Subramanian, J. & Simon, R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J. Natl. Cancer Inst. 102, 464-474 (2010).
8. Dalton, W.S. & Friend, S.H. Cancer biomarkers: an invitation to the table. Science 312, 1165-1168 (2006).
9. Ein-Dor, L., Zuk, O. & Domany, E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc. Natl. Acad. Sci. USA 103, 5923-5928 (2006).
10. Ransohoff, D.F. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4, 309-314 (2004).
11. Varmus, H. Ten years on: the human genome and medicine. N. Engl. J. Med. 362, 2028-2029 (2010).
12. Lee, H.K., Hsu, A.K., Sajdak, J., Qin, J. & Pavlidis, P. Coexpression analysis of human genes across many microarray data sets. Genome Res. 14, 1085-1094 (2004).
13. Mizuno, H., Kitada, K., Nakai, K. & Sarai, A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med. Genomics 2, 18 (2009).
14. Hebestreit, K. et al. Leukemia Gene Atlas: a public platform for integrative exploration of genome-wide molecular data. PLoS ONE 7, e39148 (2012).
15. Yuan, Y. et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat. Biotechnol. 32, 644-652 (2014).
16. Newman, A.M. et al. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 12, 453-457 (2015).
17. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
18. Mantovani, A. et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin. Cancer Biol. 14, 155-160 (2004).
19. Coussens, L.M., Zitvogel, L. & Palucka, A.K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286-291 (2013).
20. Gerstein, M.B. et al. Architecture of the human regulatory network derived from ENCODE data. Nature 489, 91-100 (2012).
21. Leek, J.T. et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet. 11, 733-739 (2010).
22. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899-905 (2010).
23. Newman, A.M. & Cooper, J.B. AutoSOME: a clustering method for identifying gene expression modules without prior knowledge of cluster number. BMC Bioinformatics 11, 117 (2010).
24. Gentles, A.J., Plevritis, S.K., Majeti, R. & Alizadeh, A.A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. J. Am. Med. Assoc. 304, 2706-2715 (2010).
25. Zeuner, A., Todaro, M., Stassi, G. & De Maria, R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell 15, 692-705 (2014).
26. Myatt, S.S. & Lam, E.W.-F. The emerging roles of forkhead box (Fox) proteins in cancer. Nat. Rev. Cancer 7, 847-859 (2007).
27. Scholzen, T. & Gerdes, J. The Ki-67 protein: from the known and the unknown. J. Cell. Physiol. 182, 311-322 (2000).
28. Fergusson, J.R. et al. CD161 defines a transcriptional and functional phenotype across distinct human T cell lineages. Cell Rep. 9, 1075-1088 (2014).
29. Lachmann, A. et al. ChEA: transcription factor regulation inferred from integrating genome-wide ChIP-X experiments. Bioinformatics 26, 2438-2444 (2010).
30. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
31. Chen, X. et al. The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol. Cell. Biol. 33, 227-236 (2013).
32. Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313, 1960-1964 (2006).
33. Fridman, W.H., Pags, F., Sauts-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
34. Lewis, C.E. & Pollard, J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66, 605-612 (2006).
35. de Visser, K.E., Eichten, A. & Coussens, L.M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37 (2006).
36. Beyer, M. & Schultze, J.L. Regulatory T cells in cancer. Blood 108, 804-811 (2006).
37. Girardi, M. et al. Regulation of cutaneous malignancy by γδ T cells. Science 294, 605 (2001).
38. Haas, W., Pereira, P. & Tonegawa, S. Gamma/delta cells. Annu. Rev. Immunol. 11, 637-685 (1993).
39. Fridlender, Z.G. & Albelda, S.M. Tumor-associated neutrophils: friend or foe? Carcinogenesis 33, 949-955 (2012).
40. Di Carlo, E. et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345 (2001).
41. Vakkila, J. & Lotze, M.T. Inflammation and necrosis promote tumour growth. Nat. Rev. Immunol. 4, 641-648 (2004).
42. Sica, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727 (2006).
43. Teramukai, S. et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur. J. Cancer 45, 1950-1958 (2009).
44. de Visser, K.E., Korets, L.V. & Coussens, L.M. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7, 411-423 (2005).
45. Liyanage, U.K. et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169, 2756-2761 (2002).
46. Minrik, I. et al. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma. Immunol. Lett. 152, 144-150 (2013).
47. Yamanaka, T. et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 73, 215-220 (2007).
48. Paik, S. et al. A multigene assay to predict recurrence of Tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
49. Chen, X., Sun, X. & Hoshida, Y. Survival analysis tools in genomics research. Hum. Genomics 8, 21 (2014).
50. Alizadeh, A.A. et al. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 118, 1350-1358 (2011).
51. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
52. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48-61 (2015).
53. Gabrilovich, D.I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
54. Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
55. Ribas, A. Tumor immunotherapy directed at PD-1. N. Engl. J. Med. 366, 2517-2519 (2012).
56. Day, A., Carlson, M.R., Dong, J., OConnor, B.D. & Nelson, S.F. Celsius: a community resource for Affymetrix microarray data. Genome Biol. 8, R112 (2007).
57. Dai, M. et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005).
58. Gautier, L., Cope, L., Bolstad, B.M. & Irizarry, R.A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315 (2004).
59. Gentleman, R.C. et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5, R80 (2004).
60. Irizarry, R.A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003).
61. Wu, Z., Irizarry, R.A., Gentleman, R., Martinez-Murillo, F. & Spencer, F. A model-based background adjustment for oligonucleotide expression arrays. J. Am. Stat. Assoc. 99, 909-917 (2004).
62. McCall, M.N., Bolstad, B.M. & Irizarry, R.A. Frozen robust multiarray analysis (fRMA). Biostatistics 11, 242-253 (2010).
63. Piccolo, S.R. et al. A single-sample microarray normalization method to facilitate personalized-medicine workflows. Genomics 100, 337-344 (2012).
64. Zhu, Y., Qiu, P. & Ji, Y. TCGA-Assembler: open-source software for retrieving and processing TCGA data. Nat. Methods 11, 599-600 (2014).
65. Liptk, T. On the combination of independent tests. Magyar Tud. Akad. Mat. Kutato Int. Kzl 3, 171-196 (1958).
66. Stouffer, S., DeVinney, L. & Suchmen, E. The American Soldier: Adjustment During Army Life (Princeton University Press, 1949).
67. Zaykin, D.V. Optimally weighted Z-test is a powerful method for combining probabilities in meta-analysis. J. Evol. Biol. 24, 1836-1841 (2011).
68. Johnson, W.E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127 (2007).
69. Storey, J.D. & Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 100, 9440-9445 (2003).
70. Szklarczyk, D. et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-D568 (2011).
71. Fiedler, M. Algebraic connectivity of graphs. Czech. Math. J. 23, 298-305 (1973).
72. Chen, J., Bardes, E.E., Aronow, B.J. & Jegga, A.G. ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37, W305-W311 (2009).
73. Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739-1740 (2011).
74. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
75. Zhong, Y. & Liu, Z. Gene expression deconvolution in linear space. Nat. Methods 9, 8-9 (2012).
76. Xu, L. et al. Gene expression changes in an animal melanoma model correlate with Aggressiveness of Human Melanoma Metastases. Mol. Cancer Res. 6, 760-769 (2008).
77. Su, L.-J. et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. BMC Genomics 8, 140 (2007).
78. Landi, M.T. et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 3, e1651 (2008).
79. Brunner, A.L. et al. Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biol. 13, R75 (2012).
80. Holmes, S., Kapelner, A. & Lee, P.P. An interactive java statistical image segmentation system: Gemident. J. Stat. Softw. 30, i10 (2009).